Robert’s Journey With EGFR+ Metastatic NSCLC

Opinion
Video

Profiling a 58-year-old retired construction manager with Stage IV EGFR+ NSCLC, discussing his transition from osimertinib to amivantamab plus chemotherapy, managing side effects, and maintaining hope throughout his treatment journey.

Recent Videos
Man in suit standing in front of blue watercolor Oncology Nursing News backdrop
Image of a woman in front of a blue Oncology Nursing News-branded backdrop.
Related Content